Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors

Abstract Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer. Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9), and designed a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yongjia Hao, Jiankun Lyu, Rong Qu, Deheng Sun, Zhenjiang Zhao, Zhuo Chen, Jian Ding, Hua Xie, Yufang Xu, Honglin Li
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ec058e038ab0407bb9e8ffb910e0f32f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec058e038ab0407bb9e8ffb910e0f32f
record_format	dspace
spelling	oai:doaj.org-article:ec058e038ab0407bb9e8ffb910e0f32f2021-12-02T15:05:01ZStructure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors10.1038/s41598-017-04184-92045-2322https://doaj.org/article/ec058e038ab0407bb9e8ffb910e0f32f2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04184-9https://doaj.org/toc/2045-2322Abstract Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer. Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9), and designed a series of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one derivatives as novel mutant-selective EGFR inhibitors. Finally, the most representative compound 20a was identified, which showed high selectivity at both enzymatic and cellular levels against EGFRL858R/T790M (H1975 cell lines) over EGFRWT (A431 cell lines). The representative compound 20a also showed promising antitumor efficiency in the in vivo antitumor efficacy study of H1975 xenograft mouse model driven by EGFRL858R/T790M. These results provide a new scaffold for the treatment of dual-mutant-driven non-small cell lung cancer.Yongjia HaoJiankun LyuRong QuDeheng SunZhenjiang ZhaoZhuo ChenJian DingHua XieYufang XuHonglin LiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yongjia Hao Jiankun Lyu Rong Qu Deheng Sun Zhenjiang Zhao Zhuo Chen Jian Ding Hua Xie Yufang Xu Honglin Li Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors
description	Abstract Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer. Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9), and designed a series of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one derivatives as novel mutant-selective EGFR inhibitors. Finally, the most representative compound 20a was identified, which showed high selectivity at both enzymatic and cellular levels against EGFRL858R/T790M (H1975 cell lines) over EGFRWT (A431 cell lines). The representative compound 20a also showed promising antitumor efficiency in the in vivo antitumor efficacy study of H1975 xenograft mouse model driven by EGFRL858R/T790M. These results provide a new scaffold for the treatment of dual-mutant-driven non-small cell lung cancer.
format	article
author	Yongjia Hao Jiankun Lyu Rong Qu Deheng Sun Zhenjiang Zhao Zhuo Chen Jian Ding Hua Xie Yufang Xu Honglin Li
author_facet	Yongjia Hao Jiankun Lyu Rong Qu Deheng Sun Zhenjiang Zhao Zhuo Chen Jian Ding Hua Xie Yufang Xu Honglin Li
author_sort	Yongjia Hao
title	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors
title_short	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors
title_full	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors
title_fullStr	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors
title_full_unstemmed	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors
title_sort	structure-guided design of c4-alkyl-1,4-dihydro-2h-pyrimido[4,5-d][1,3]oxazin-2-ones as potent and mutant-selective epidermal growth factor receptor (egfr) l858r/t790m inhibitors
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/ec058e038ab0407bb9e8ffb910e0f32f
work_keys_str_mv	AT yongjiahao structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT jiankunlyu structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT rongqu structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT dehengsun structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT zhenjiangzhao structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT zhuochen structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT jianding structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT huaxie structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT yufangxu structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors AT honglinli structureguideddesignofc4alkyl14dihydro2hpyrimido45d13oxazin2onesaspotentandmutantselectiveepidermalgrowthfactorreceptoregfrl858rt790minhibitors
_version_	1718388990470520832

Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors

Ejemplares similares